KR20240132501A - 우울증 치료를 위한 조성물 및 방법 - Google Patents

우울증 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20240132501A
KR20240132501A KR1020247026652A KR20247026652A KR20240132501A KR 20240132501 A KR20240132501 A KR 20240132501A KR 1020247026652 A KR1020247026652 A KR 1020247026652A KR 20247026652 A KR20247026652 A KR 20247026652A KR 20240132501 A KR20240132501 A KR 20240132501A
Authority
KR
South Korea
Prior art keywords
patient
treatment
esketamine
articaprant
antidepressant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247026652A
Other languages
English (en)
Korean (ko)
Inventor
웨인 씨. 드레베츠
하트무스 크리스찬 콜브
지아드 세르할 사드
Original Assignee
얀센 파마슈티칼즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티칼즈, 인코포레이티드 filed Critical 얀센 파마슈티칼즈, 인코포레이티드
Publication of KR20240132501A publication Critical patent/KR20240132501A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/5412—IL-6

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Otolaryngology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247026652A 2022-01-10 2023-01-09 우울증 치료를 위한 조성물 및 방법 Pending KR20240132501A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263298060P 2022-01-10 2022-01-10
US63/298,060 2022-01-10
PCT/IB2023/050171 WO2023131921A1 (en) 2022-01-10 2023-01-09 Compositions and methods for the treatment of depression

Publications (1)

Publication Number Publication Date
KR20240132501A true KR20240132501A (ko) 2024-09-03

Family

ID=84981673

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247026652A Pending KR20240132501A (ko) 2022-01-10 2023-01-09 우울증 치료를 위한 조성물 및 방법

Country Status (10)

Country Link
US (1) US20250064779A1 (https=)
EP (1) EP4463143A1 (https=)
JP (1) JP2025503649A (https=)
KR (1) KR20240132501A (https=)
CN (1) CN118843459A (https=)
AU (1) AU2023206048A1 (https=)
CA (1) CA3247733A1 (https=)
IL (1) IL314176A (https=)
MX (1) MX2024008619A (https=)
WO (1) WO2023131921A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19723133A1 (de) 1997-06-03 1998-12-10 Caideil M P Teoranta Tourmakea Austragvorrichtung für Medien
WO2009094260A1 (en) * 2008-01-22 2009-07-30 Eli Lilly And Company Kappa selective opioid receptor antagonist
JP2022548233A (ja) * 2019-09-13 2022-11-17 ヤンセン ファーマシューティカルズ，インコーポレーテッド エスケタミンの鼻腔内投与

Also Published As

Publication number Publication date
EP4463143A1 (en) 2024-11-20
MX2024008619A (es) 2024-09-25
CN118843459A (zh) 2024-10-25
IL314176A (en) 2024-09-01
JP2025503649A (ja) 2025-02-04
US20250064779A1 (en) 2025-02-27
WO2023131921A1 (en) 2023-07-13
CA3247733A1 (en) 2023-07-13
AU2023206048A1 (en) 2024-08-29

Similar Documents

Publication Publication Date Title
JP7807870B2 (ja) うつ病の治療のためのエスケタミン
JP2024516297A (ja) うつ病の治療のための組成物及び方法
US12150929B2 (en) Compositions and methods for the treatment of depression
US20220304950A1 (en) Esketamine for the treatment of patients with major depressive disorder, including suicidality
JP2025508069A (ja) アチカプラントを含む組成物
US20250221960A1 (en) Compositions and methods for the treatment of depression
JP2025502098A (ja) うつ病の治療のための組成物及び方法
KR20240132501A (ko) 우울증 치료를 위한 조성물 및 방법
US20250177350A1 (en) Compositions and methods for the treatment of depression
US20240238245A1 (en) Compositions and methods for the treatment of depression
JP7840873B2 (ja) うつ病の治療方法
EA050800B1 (ru) Композиции и способы лечения депрессии
CN117615757A (zh) 用于治疗抑郁症的组合物和方法
JP2012533547A (ja) 治療のためのエキソ−ｓ−メカミラミンの方法、使用、及び化合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240808

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application